Carlos A. Camargo, MD, DrPH
Associate Professor of Medicine and Epidemiology
Harvard Medical School
Massachusetts General Hospital
Howard J. Garber, MD, MPH
Johns Hopkins HealthCare, LLC
Glen Burnie, MD
THIS PROGRAM WAS ORIGINALLY RELEASED AS A LIVE AUDIOCONFERENCE SERIES BEGINNING ON NOVEMBER 26, 2007. IF YOU RECEIVED CME OR CPE CREDIT FOR THE AUDIOCONFERENCE, YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ONLINE VERSION.
Over 22 million Americans have asthma, and effective asthma management poses both challenges and opportunities. Educating physicians, pharmacists, and patients on the need for better use of long-term control medications (e.g., inhaled corticosteroids) versus rescue medications (e.g., albuterol) is important to achieve optimal care and outcomes. The new National Asthma Education and Prevention Program (NAEPP) guidelines stress the assessment of asthma severity and control as a means of selecting and titrating treatment.
Experts in asthma care recognize the need for improving asthma management in managed care settings. Managed care medical and pharmacy directors, clinicians, and pharmacists have key roles as decision makers in promoting proper care, be it either through guideline adherence or appropriate referrals to specialists. In addition, the medical literature highlights provider education and utilization of disease management (DM) programs as just a couple of ways that managed care decision makers stand to influence and improve asthma management and outcomes. By gaining familiarity with the new NAEPP asthma guidelines and key strategies for quality improvement and cost containment, managed care organizations will have the opportunity to positively impact not only their members’ health outcomes, but their expenditures.
In this program, faculty will provide an overview of the new NAEPP guidelines, and hone in on the key components and changes from earlier versions. They will describe a variety of strategies, targeting clinical, administrative and coverage options, that managed care organizations can consider implementing.
. Target Audience
Managed care medical directors, pharmacy directors, and other physicians and pharmacists interested in the management of asthma.
Upon completion of this educational activity, the participant should be able to:
Discuss the epidemiology and public health burden of asthma.
Summarize the new NAEPP guidelines.
Describe the NAEPP guidelines’ stepwise approach to pharmacotherapy based on asthma severity and control.
Review the NAEPP guidelines’ recommendations on therapies for asthma exacerbations and maintenance therapy.
Outline components of various strategies to increase the use of appropriate asthma therapies.
It is the policy of NAMCP to ensure independence, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NAMCP prior to accreditation of the activity.
Carlos A. Camargo, MD, DrPH has received funding for clinical research from AstraZeneca; GlaxoSmithKline; Merck and Co., Inc; Respironics; and Novartis Pharmaceuticals Corporation. He is on the speakers’ bureau for AstraZeneca; GlaxoSmithKline; and Merck and Co., Inc; and is a consultant to AstraZeneca; Novartis Pharmaceuticals Corporation; Schering-Plough Corporation; and Dey.
Howard J. Garber, MD, MPH has no financial interests to disclose.
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the National Association of Managed Care Physicians (NAMCP) and Medical Communications Media, Incorporated. NAMCP is accredited by the ACCME to provide continuing medical education for physicians.
NAMCP designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Pharmacists: ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Program Numbers 221-999-08-005-H01-P/T have been assigned to this activity (initial release date 2-29-2008). This program is approved for 1.0 contact hours (0.10 CEUs) in states that recognize ACPE providers. The program is provided at no cost to participants. Participants must pass the post-test with a score of 70% or higher and complete the program evaluation to receive pharmacy CE credit. No partial credit will be given. Commercial Support Statements
Please turn off all pop-up blockers.
Click on the “start program” icon. This will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or update/correct existing registration information. When ready, click on the “continue to program” icon at the bottom of the screen. This will take you to a brief pre-program survey.
The next screen will permit you to check for or download the Flash player required to run this program.
Clicking “start the virtual meeting” will allow you to begin the program presentation. This activity will require approximately 60 minutes to complete.
Upon completion of the program, click on the post-test button to access the post-test and program evaluation. This will bring you to a brief post-program survey.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME/CPE statement of credit. Two attempts are allowed.
©2007, Medical Communications Media, Inc. All Rights Reserved.
None of the contents may be reproduced in any form without prior written permission of the publisher. The opinions expressed in this activity are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the National Association of Managed Care Physicians, ProCE, Inc., or AstraZeneca. Any medications or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and of possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.